With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
You may also be interested in...
Abbvie business starts sales of Lastacaft (alcaftadine solution/0.25%) eye drops, licensed from innovator Vistakon Pharmaceuticals, approved through an sNDA. Full switch removes Lastacaft from Rx sales in US.
Canadian firm plans to separate Solta first, with an IPO in December or January, and at least 30 days later offer shares in Bausch + Lomb. Order of IPOs could change, though.
Bausch + Lomb’s Alaway Preservative-Free antihistamine eye drops launch in US, The Bausch Health Companies division planned as spin-out also recently gained South Korean approval for its Lumify OTC redness reliever drops and has submissions under review in other countries.